Evidence map›Paper›PMID 40487166›Full record

ReviewMaterials today. Bio2025

Bioactive polydopamine nanomedicines-assisted cancer immunotherapy.

Xionghongcan Zhou, Lihua Wang, Yayang Wu, Xiaoping Lin, Fen Liu, Xiaoxia Sun, Kaiyue Song, Cong Jiang, Feng Zhao, Xianglong Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xionghongcan ZhouJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Lihua WangJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Yayang WuJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Xiaoping LinInstitute of New Energy Materials Engineering, School of New Energy Industry, Jiangxi Hongzhou Vocational College, YiChun, 331100, China.
Fen LiuInstitute of New Energy Materials Engineering, School of New Energy Industry, Jiangxi Hongzhou Vocational College, YiChun, 331100, China.
Xiaoxia SunJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Kaiyue SongJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Cong JiangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200092, China.
Feng ZhaoJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Xianglong LiJiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy, which activates the patient's immune system to combat tumors, has made significant progress in recent years. However, the immunosuppressive nature of the tumor microenvironment and the side effects associated with systemic administration limit its efficacy. Taking advantage of bioactive polydopamine (PDA) materials in controlled drug and immunomodulator release owing to their unique physicochemical properties and biocompatibility, recent efforts have focused on engineered PDA nanomedicines with intrinsic immunomodulatory functions, but relevant systematic reviews are lacking. This review summarizes recent advances in the application of bioactive PDA nanomedicines in cancer immunotherapy, focusing on their roles in inducing immunogenic cell death, reprogramming tumor-associated macrophages, as cancer vaccine, and enhancing immune checkpoint blockade. With further in-depth discussion of the challenges and future perspectives of bioactive PDA nanomedicines, with the aim that this systematic review can promote interdisciplinary intersections and provide inspiration for the further growth and clinical translation of PDA materials.

Indexed as

BioactiveCancer immunotherapyNanomedicinePolydopamine

Identifiers

PMID40487166
PMCPMC12145715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.